Synopsis Neurotrophic Keratitis is a rare disease with an estimated prevalence of 1.6 – 4.2 cases per 10,000 persons. Trigeminal nerve damage may cause neurotrophic keratitis (NK) with partial or total loss of corneal sensation, leading to visual impairment and potentially permanent blindness. The present study evaluates the safety and efficacy of topical recombinant human nerve growth factor (rhNGF) for treating moderate-to-severe neurotrophic keratitis (NK). This week’s “ MED FACT ” discusses a randomized control trial from Ophthalmology, “ Phase 2 Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis ”. Authors: S.
Bonini et. al. Key Takeaways Topical rhNGF is safe and more effective than vehicle in promoting healing of moderate to severe NK. Objective: The present study assesses the safety and efficacy of two dose…
